Can cancer clinical trials be fixed?

Nature Biotechnology

Volumn 29, Issue 1, 2011, Pages 13-15

  Allison, Malorye ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMTUZUMAB OZOGAMICIN; IMATINIB; LAPATINIB; OBLIMERSEN; PACLITAXEL; PLX 4032; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER CENTER; CANCER RESEARCH; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG MANUFACTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG CANCER; MELANOMA; NEOPLASM; NOTE; ONCOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOTECHNOLOGY; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG INDUSTRY; FEMALE; HUMANS; MAYTANSINE; NEOPLASMS; PATIENT ADVOCACY; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78651272141     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1746     Document Type: Note

References (12)

1. Allison, M. Nat. Biotechnol. 28, 879-880 (2010)
2. Merrill, J. The Pink Sheet Daily, Elsevier Business Intelligence, 27 August 2010.
3. Vogel, C.L. et al. J. Clin. Oncol. 27 Supplement, 1017 (2009).
4. Mulcahy, N. Medscape Today, 〈http://www.medscape.com/viewarticle/ 703912〉 4 June 2009.
5. Bollag, G. et al. Nature 467, 596-599 (2010).
6. Harmon, A. The New York Times, p.1, 18 September 2010.
7. Soda, M. et al. Nature 448, 561-566 (2007).
8. Anonymous. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products (FDA, March 2004). 〈http://www.fda. gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ucm077262.htm〉
9. Anonymous. Qualification Process for Drug Development Tools. Draft Guidance (US Department of Health and Human Services, FDA, CDER, October 2010). 〈http:// www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM230597.pdf〉
10. Allison, M. Nat. Biotechnol. 28, 383-384 (2010).
11. Richey, E.A. et al. J. Clin. Oncol. 27, 4398-4405 (2009).
12. Lanthier, M. & Sridhara, R. J. Clin. Oncol. 28, e226 (2010).